Cargando…

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients

BACKGROUND: We aimed to verify the role of hENT1 as a prognostic predictor for patients with resectable pancreatic ductal adenocarcinoma (PDAC) who underwent radical resection followed by intra-arterial infusion of gemcitabine-based regimen. METHODS: We collected surgical samples from 102 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Yu, Xinzhe, Li, Hengchao, Yang, Chuanxin, Jin, Chen, Huang, Xinyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909848/ https://www.ncbi.nlm.nih.gov/pubmed/36755224 http://dx.doi.org/10.1186/s12876-023-02666-x

Ejemplares similares

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
por: Elander, N. O., et al.
Publicado: (2018)

Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022)

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine
por: Kalloger, Steve E, et al.
Publicado: (2017)

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency
por: Al-Ansari, Mohammad, et al.
Publicado: (2015)

Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?
por: Jiraskova, Lucie, et al.
Publicado: (2019)

Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): Evidence for allosteric kinetics at acidic pH
por: Tandio, David, et al.
Publicado: (2019)

Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

SKM-1细胞地西他滨耐药机制中hENT1功能的研究
Publicado: (2015)

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?
por: Giacometti, Cinzia, et al.
Publicado: (2023)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy
por: Liu, Chen, et al.
Publicado: (2020)

Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
por: Hwang, Dae Wook, et al.
Publicado: (2020)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)

Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
por: Liu, Xiaoyu, et al.
Publicado: (2016)

Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy
por: Matsui, Hiroto, et al.
Publicado: (2017)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011)

An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
por: Yu, Xinzhe, et al.
Publicado: (2015)

Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy
por: Aoyama, Toru, et al.
Publicado: (2017)

Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma
por: Habermehl, Daniel, et al.
Publicado: (2015)

FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
por: Hu, Qiangsheng, et al.
Publicado: (2017)

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
por: Blackstock, A W, et al.
Publicado: (2006)

Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone
por: Chen, Hua, et al.
Publicado: (2018)

Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series
por: Alam, Salma, et al.
Publicado: (2018)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine
por: Aoyama, Toru, et al.
Publicado: (2017)

The Association of FLT3-ITD Gene Mutation with Bone Marrow Blast Cell Count, CD34, Cyclin D1, Bcl-xL and hENT1 Expression in Acute Myeloid Leukemia Patients
por: Notopuro, Paulus Budiono, et al.
Publicado: (2020)

Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases
por: Yu, Xinzhe, et al.
Publicado: (2017)

Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life
por: Toyama, Yoichi, et al.
Publicado: (2013)

Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy
por: Yakabe, Tomomi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_72f3cv4lss75gpg5drodhe60tv